Francesca Maria Gaiani
A5086772020- Viral-associated cancers and disorders
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Autoimmune Bullous Skin Diseases
- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- HIV/AIDS drug development and treatment
- Research on Leishmaniasis Studies
- CNS Lymphoma Diagnosis and Treatment
- Rheumatoid Arthritis Research and Therapies
- Sarcoma Diagnosis and Treatment
- Antifungal resistance and susceptibility
- Vascular Tumors and Angiosarcomas
- Histiocytic Disorders and Treatments
- Immunodeficiency and Autoimmune Disorders
- Tuberculosis Research and Epidemiology
- Cancer and Skin Lesions
- Nonmelanoma Skin Cancer Studies
- Infectious Disease Case Reports and Treatments
- Reproductive tract infections research
- Rabies epidemiology and control
- Infectious Diseases and Mycology
- Musculoskeletal synovial abnormalities and treatments
IRCCS Policlinico San Donato
2017-2025
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2013-2024
University of Milan
2008-2016
Ospedale Maggiore
2008-2014
Istituti di Ricovero e Cura a Carattere Scientifico
2008-2014
Bimekizumab is a monoclonal antibody that targets Interleukin-17 A and F, approved for the treatment of moderate-to-severe plaque psoriasis. While bimekizumab has been evaluated in several phase-III clinical trials, real-world evidence still very limited.This multicenter retrospective study included patients affected by psoriasis treated with from May 1, 2022 to April 30, 2023, at 19 Italian referral hospitals. Patients eligible systemic treatments were included. The effectiveness was terms...
The development of several effective biological drugs for moderate-to-severe plaque psoriasis has dramatically changed the lives patients. Despite wide use interleukin (IL) inhibitors, limited data are available to date regarding long-term treatment persistence.
Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians formidable challenges treatment. While new biologic drugs have emerged as safe and effective options for managing their efficacy challenging-to-treat areas remains inadequately explored. Intriguingly, studies shown that interleukin (IL)-17 inhibitors exhibit effectiveness addressing genital psoriasis. Objectives: We aimed to determine the profile bimekizumab affected by...
Guselkumab is a fully human monoclonal antibody that binds selectively to the p19 subunit of interleukin-23, which has shown efficacy in patients with previous incomplete response ustekinumab NAVIGATE clinical trial. [Correction added on [28-02-2023], after first online publication: 'humanized antibody' been changed 'fully preceding sentence.] OBJECTIVES: We conducted 104-week multicenter retrospective study assess effectiveness and safety guselkumab affected by plaque psoriasis an...
Background: Interleukin (IL) inhibitors are increasingly used in the management of moderate-to-severe plaque psoriasis. However, their use patients with a history cancer is debated.
Brodalumab is a monoclonal antibody that targets the subunit A of interleukin-17A receptor (IL17RA), inhibiting signaling various isoforms IL-17 family. It has been approved for treatment moderate-to-severe plaque psoriasis after being evaluated in three Phase-3 trials. However, long-term data on brodalumab real-life setting are still limited.The aim this study was to evaluate effectiveness and safety psoriasis. We also assessed drug survival 3 years timespan. conducted retrospective...
Background: Risankizumab is a humanized monoclonal antibody that selectively inhibits interleukin-23. It has been approved for moderate-to-severe plaque psoriasis and shown efficacy safety in clinical trials real-world experiences. This study aimed to evaluate the long-term effectiveness, safety, drug survival of risankizumab real-life setting. Materials Methods: We included patients treated with from January 2019 February 2023. A Psoriasis Area Severity Index score (PASI) was collected at...
Journal Article Intralesional vincristine as first‐line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study 151 patients Get access L. Brambilla, Brambilla Department of Anesthesia, Intensive Care and Dermatologic Sciences, Università degli Studi di Milano, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, 20122 Milan, Italy Search other works by this author on: Oxford Academic Google Scholar M. Bellinvia, Bellinvia Monica Bellinvia. E‐mail:...
Additional data supporting the findings of this manuscript are available on reasonable request to corresponding author.
Purpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment moderate-to-severe plaque psoriasis in two dosages. We conducted 16-week multicenter retrospective study to compare effectiveness and safety tildrakizumab 200 mg versus 100 patients with high disease burden or body weight.
Objective: This European, multicentric, retrospective study aimed to collect data on secukinumab effectiveness in a real-world setting.Research design and methods: All psoriatic patients starting between January 2016 February 2017 11 European centers were followed until 2018 retrospectively evaluated.Main outcome measures: Secukinumab was assessed by relative improvement from baseline of the Psoriasis Area Severity Index (PASI) absolute PASI score modifications throughout 52 weeks therapy....
The introduction of biological therapies has revolutionized the treatment moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor interleukin-17A, shown great results in terms efficacy and safety both clinical trials real-world experiences. However, there is a lack long-term data available for ixekizumab. We conducted multicenter real-life study to evaluate effectiveness ixekizumab patients with Psoriasis Area Severity Index score (PASI) was collected at baseline after...
<p>Supplementary Table 3 shows the clinical treatment-related AEs by SOC and study phases.</p>
<p>Supplementary Table 5 summarizes the representativeness of study participants</p>
<p>Supplementary Table 1 shows the active concurrent illnesses at baseline.</p>
<p>Supplementary Table 4 shows the treatment-related laboratory AE by SOC, preferred terms and study phases.</p>
<p>Supplementary Table 2 shows the treatment-related AE numbers by study phases.</p>
The aim of this multicenter observational study is to report data from real world on the use bimekizumab in patients aged ≥ 65 years with moderate-to-severe plaque psoriasis. Elderly are poorly represented clinical trials for psoriasis, and real-world studies important guide choices.